Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Nio Stock Is on the Verge of a Dip, so Get Ready to Pounce

By Chris Lau, InvestorPlace Contributor

Nio is entering a seasonally weak period, creating a buying opportunity for investors who missed the uptrend.

This Sports Betting License Is a Massive Catalyst for Fubo Stock

By Chris Lau, InvestorPlace Contributor

fuboTV is about to accelerate its growth in the sports betting market as it gains approvals in more U.S. states.

7 Busted Biotech Stocks Due for a Rebound

By Chris Lau, InvestorPlace Contributor

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally.

Alibaba is a Speculative Trade With a 5-Year Time Frame

By Chris Lau, InvestorPlace Contributor

BABA stock may prove to be a long-term value play, but shares are likely to remain under pressure amid China's regulatory crackdown.

Novavax Stock Is a Steal Here If You Believe It Will Come Through

By Chris Lau, InvestorPlace Contributor

When it ships an approved Covid-19 vaccine, Novavax is poised for sharp growth for many quarters, as countries grapple to vaccinate people.

Load More